Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors

2019 ◽  
Vol 26 (3) ◽  
pp. 199-207 ◽  
Author(s):  
Rita Del Pinto ◽  
Davide Grassi ◽  
Giuliana Properzi ◽  
Giovambattista Desideri ◽  
Claudio Ferri
Keyword(s):  
Potential Role ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Atherosclerotic Disease ◽  
Causal Role ◽  
Low Density ◽  
Pcsk9 Inhibitors

scholarly journals Inclisirán as an alternative treatment for Hypercholesterolemia

2021 ◽  
Vol 12 (3) ◽  
pp. 517-521
Author(s):  
Jorge Andrés Ojeda Villota ◽  
Javier Alfredo Pérez Martínez ◽  
Luis Alberto Burgos de Moya ◽  
Rodrigo Alfonso Chavez Vega ◽  
Roxana Rivera Valencia ◽  
...  
Keyword(s):  
Risk Factors ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Low Density ◽  
Pcsk9 Inhibitors ◽  
Cholesterol Levels ◽  
Lowering Therapy

Hypercholesterolemia (CH) is defined as the elevation of serum cholesterol levels, especially low-density lipoprotein (LDL) cholesterol, which is considered to be one of the most relevant risk factors for triggering cardiovascular disease, for This is vitally important to start treatment, there are several highly useful pharmacological groups for lipid-lowering therapy, among them we highlight the PCSK9 inhibitors, among the molecules that are part of this group we find inclisirán, this being a structure that promises a lot in regarding the management of hypercholesterolemia.

scholarly journals The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Atherosclerosis Development

2019 ◽  
Vol 5 (5) ◽  
pp. 112-120 ◽  
Author(s):  
A. Chaulin ◽  
L. Karslyan ◽  
A. Aleksandrov ◽  
A. Mazaev ◽  
E. Grigorieva ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
New Drugs ◽  
Low Density ◽  
Proprotein Convertase ◽  
Pcsk9 Inhibitors ◽  
Residual Cardiovascular Risk ◽  
Promising Therapeutic Target ◽  
Atherosclerosis Development

Elevated plasma low-density lipoprotein cholesterol (LDL-C) is an important risk factor for cardiovascular diseases. Statins are the most widely used therapy for patients with hyperlipidemia. However, a significant residual cardiovascular risk remains in some patients even after maximally tolerated statin therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new promising therapeutic target for decreasing LDL-C. PCSK9 reduces LDL intake from circulation by enhancing low-density lipoprotein receptors (LDLR) degradation and preventing LDLR recirculation to the cell surface. In addition to examining the functional role of PCSK9, this review also discusses new drugs for the treatment of hyperlipidemia — PCSK9 inhibitors.

Sign in / Sign up

Export Citation Format

Share Document